Mediterranean Journal of Rheumatology最新文献_第4页

New-Onset MDA-5 Dermatomyositis in a Patient Following COVID-19 Vaccination: A Case Report. 一名患者接种 COVID-19 疫苗后新发 MDA-5 皮肌炎：病例报告。

Mediterranean Journal of Rheumatology Pub Date : 2024-03-31 eCollection Date: 2024-03-01 DOI: 10.31138/mjr.280124.nom

Eleana Bolla, George E Fragoulis, Alexios Iliopoulos

{"title":"New-Onset MDA-5 Dermatomyositis in a Patient Following COVID-19 Vaccination: A Case Report.","authors":"Eleana Bolla, George E Fragoulis, Alexios Iliopoulos","doi":"10.31138/mjr.280124.nom","DOIUrl":"10.31138/mjr.280124.nom","url":null,"abstract":"Vaccination against Sars-CoV-2 has been proven to significantly reduce COVID-19 morbidity and mortality and is therefore recommended for the general population, and especially for seniors with impaired immunity. However, it is currently postulated that COVID-19 vaccines could rarely induce autoimmune diseases in previously healthy individuals. We report a case of new-onset anti-melanoma differentiation-associated protein 5 (anti-MDA5) antibody-positive dermatomyositis in a patient presenting with rash and fever following the third dose of COVID-19 vaccine. The laboratory testing revealed high titres of anti-MDA-5 antibody and chest computed tomography showed micronodular lesions and ground glass opacities bilaterally. The patient was promptly treated with corticosteroids, methotrexate, and azathioprine, and was later started on rituximab due to dermatomyositis rash exacerbation along with newly formed, diffuse skin ulcers. Our case highlights the potential immunogenicity of COVID-19 vaccines and the need for further reporting of rare rheumatic syndromes possibly related to COVID-19 disease and vaccination.","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"35 1","pages":"179-183"},"PeriodicalIF":0.0,"publicationDate":"2024-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11082759/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140912935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Anakinra for Refractory Pseudogout in Patients with End-stage Renal Disease on Haemodialysis. Anakinra 用于治疗血液透析终末期肾病患者的难治性假性痛风。

Mediterranean Journal of Rheumatology Pub Date : 2024-03-30 eCollection Date: 2024-03-01 DOI: 10.31138/mjr.261123.afr

Christina Antoniadou, Nikolaos Fytanidis, Vasileios Devetzis, Konstantia Kantartzi, Charalampos Papagoras

{"title":"Anakinra for Refractory Pseudogout in Patients with End-stage Renal Disease on Haemodialysis.","authors":"Christina Antoniadou, Nikolaos Fytanidis, Vasileios Devetzis, Konstantia Kantartzi, Charalampos Papagoras","doi":"10.31138/mjr.261123.afr","DOIUrl":"https://doi.org/10.31138/mjr.261123.afr","url":null,"abstract":"Calcium pyrophosphate deposition (CPPD) arthritis is the second most common type of crystal-induced arthritis after gout. Acute flares are commonly treated with non-steroidal anti-inflammatory drugs, intra-articular or short-term systemic glucocorticoids or colchicine. However, since there is no pharmacological treatment to reduce CPPD crystal burden, relapsing or chronic CPPD arthritis may be challenging to treat, particularly in patients with end-stage renal disease who are at risk for toxicity of the above medications. Since IL-1β appears to be driving CPPD arthritis, we treated two patients with chronic CPPD arthritis and end-stage renal disease on haemodialysis with the IL-1β receptor antagonist anakinra. In both patients, arthritis resolved quickly, while continuation of anakinra maintained remission and allowed complete glucocorticoid withdrawal. Therefore, anakinra may be a safe and effective option both for short and long-term treatment of CPPD arthritis in patients on chronic renal replacement therapy.","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"35 Suppl 1","pages":"58-62"},"PeriodicalIF":0.0,"publicationDate":"2024-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11094439/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140958427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnosing and Treating Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still's Disease as Part of the Still's Disease Continuum. 诊断和治疗系统性幼年特发性关节炎和成年型斯蒂尔病，将其作为斯蒂尔病连续体的一部分。

Mediterranean Journal of Rheumatology Pub Date : 2024-03-30 eCollection Date: 2024-03-01 DOI: 10.31138/mjr.290323.dat

Apostolos Kontzias, Olga Petryna, Priscila Nakasato, Petros Efthimiou

{"title":"Diagnosing and Treating Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still's Disease as Part of the Still's Disease Continuum.","authors":"Apostolos Kontzias, Olga Petryna, Priscila Nakasato, Petros Efthimiou","doi":"10.31138/mjr.290323.dat","DOIUrl":"https://doi.org/10.31138/mjr.290323.dat","url":null,"abstract":"Aim: We have summarised the existing evidence supporting the concept that systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still's disease (AOSD) are part of the same Still's disease spectrum.Methods: A PubMed/Embase database search was conducted using specific search strings and free text words to screen for relevant articles. The search was limited to studies in humans, published up to June 2023, in English-language.Summary: sJIA and AOSD are rare autoinflammatory disorders that have similar pathophysiological and clinical features. The clinical presentations of sJIA and AOSD are highly variable, with differential diagnoses that include a broad range of malignancies, infectious diseases, and autoimmune disorders, which contribute to delays in diagnosis. Several sets of classification exist to help diagnose patients in clinical practice; the International League of Associations for Rheumatology criteria for sJIA and the Yamaguchi and Fautrel criteria for AOSD are the most-used criteria. The therapeutic strategy for Still's disease aims to relieve signs and symptoms, prevent irreversible joint damage and potentially life-threatening complications, and avoid deleterious side effects of treatment. Recently, targeted therapies such as interleukin (IL)-1 and IL-6 inhibitors have become available for the treatment of sJIA and AOSD. While these biologics were originally largely reserved for patients in whom non-steroidal anti-inflammatory drugs, corticosteroids and conventional synthetic disease-modifying anti-rheumatic drugs had failed, they are increasingly used earlier in the treatment paradigm. Among IL-1 inhibitors, canakinumab is the only biologic approved in the US for the treatment of both sJIA and AOSD.","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"35 Suppl 1","pages":"45-57"},"PeriodicalIF":0.0,"publicationDate":"2024-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11094444/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140958881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Selective JAK-Inhibitors in Spondyloarthritis. 脊柱关节炎中的选择性 JAK 抑制剂

Mediterranean Journal of Rheumatology Pub Date : 2024-03-30 eCollection Date: 2024-03-01 DOI: 10.31138/mjr.311023.sji

Konstantinos D Vassilakis, Konstantina Magiouf, Stefan Siebert, George E Fragoulis

引用次数: 0

Focus on Filgotinib in Rheumatoid Arthritis: A Trial-Based Review. 聚焦类风湿关节炎中的 Filgotinib：基于试验的综述。

Mediterranean Journal of Rheumatology Pub Date : 2024-03-30 eCollection Date: 2024-03-01 DOI: 10.31138/mjr.281123.fof

Elpida Skouvaklidou, Dimitrios Deligeorgakis, Anastasia Skalkou, Vasileios Skepastianos, Konstantinos Tsafis, Evdokia Papadimitriou, Eleni Pagkopoulou, Paraskevi Avgerou, Maria G Mytilinaiou, Maria Tzitiridou-Chatzopoulou, Nikolaos Kougkas, Christina Adamichou

{"title":"Focus on Filgotinib in Rheumatoid Arthritis: A Trial-Based Review.","authors":"Elpida Skouvaklidou, Dimitrios Deligeorgakis, Anastasia Skalkou, Vasileios Skepastianos, Konstantinos Tsafis, Evdokia Papadimitriou, Eleni Pagkopoulou, Paraskevi Avgerou, Maria G Mytilinaiou, Maria Tzitiridou-Chatzopoulou, Nikolaos Kougkas, Christina Adamichou","doi":"10.31138/mjr.281123.fof","DOIUrl":"https://doi.org/10.31138/mjr.281123.fof","url":null,"abstract":"Janus kinases (JAK)/Signal Transducer and Activator of Transcription (STAT) pathway is involved in pathophysiologic cascade of a notable number of rheumatic diseases. The development of JAK inhibitors has expanded treatment choices in rheumatoid arthritis (RA) with a sustained class-effect efficacy. Filgotinib is a novel selective inhibitor of JAK1 isoform licensed for use in RA and ulcerative colitis. In this review we aim to present an analysis of filgotinib's efficacy and drug-specific safety warnings. Patients with RA with or without concomitant conventional synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) (naïve or experienced) and those who have failed biologic Disease-Modifying Antirheumatic Drugs (bDMARDs) were examined in randomised clinical trials. Filgotinib was also tested against placebo, methotrexate, or adalimumab. Long-term extension trials provide insights for up to four years of continuous filgotinib administration. Beneficial effects are depicted in both disease activity parameters and quality of life indexes in moderate or severe RA with a longitudinal efficacy. In head-to-head comparison with adalimumab, filgotinib 200 mg was non-inferior. Adverse effects alerts are marked by the elevated risk of infectious adverse effects with the exception of herpes zoster infection, which has a low incidence.","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"35 Suppl 1","pages":"1-9"},"PeriodicalIF":0.0,"publicationDate":"2024-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11094443/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140959190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Effect of JAK Inhibitors on Patient-Reported Outcomes in Psoriatic Arthritis. JAK抑制剂对银屑病关节炎患者报告结果的影响

Mediterranean Journal of Rheumatology Pub Date : 2024-03-30 eCollection Date: 2024-03-01 DOI: 10.31138/mjr.171223.tej

Sotirios G Tsiogkas, Carlo Perricone, Dimitrios P Bogdanos

{"title":"The Effect of JAK Inhibitors on Patient-Reported Outcomes in Psoriatic Arthritis.","authors":"Sotirios G Tsiogkas, Carlo Perricone, Dimitrios P Bogdanos","doi":"10.31138/mjr.171223.tej","DOIUrl":"https://doi.org/10.31138/mjr.171223.tej","url":null,"abstract":"Objective: Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin of patients with psoriasis. In this review we aimed to summarise the available evidence regarding the effect of Janus kinase inhibitors (JAKi) on patient-reported outcomes (PROs) when used for the management of PsA.Methods: We utilised a narrative review approach as we searched the available literature for articles to be included in our study.Results: JAKi have been found to be effective in inducing better PRO responses compared to placebo. These findings have been consistent across various patient populations, including those with active PsA, those with an inadequate response to conventional therapies, and those with comorbidities. The evidence supporting the benefits of JAKi on PROs in PsA is compelling, demonstrating consistent improvements in pain, physical function, fatigue, and quality of life.Conclusion: Numerous studies have demonstrated the the efficacy of JAKi in improving PROs in patients with PsA.","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"35 Suppl 1","pages":"20-26"},"PeriodicalIF":0.0,"publicationDate":"2024-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11094440/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140959260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

JAK Inhibition as a Potential Treatment Target in Systemic Lupus Erythematosus. 将 JAK 抑制作为系统性红斑狼疮的潜在治疗靶点

Mediterranean Journal of Rheumatology Pub Date : 2024-03-30 eCollection Date: 2024-03-01 DOI: 10.31138/mjr.231123.jia

Georgia-Savina Moysidou, Athanasia Dara

引用次数: 0

Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism with JAK Inhibitors versus TNF Inhibitors in Rheumatoid Arthritis Patients: A Systematic Review and Meta-Analysis. 类风湿性关节炎患者使用 JAK 抑制剂和 TNF 抑制剂发生主要不良心血管事件和静脉血栓栓塞的风险：系统回顾与元分析》。

Mediterranean Journal of Rheumatology Pub Date : 2024-03-30 eCollection Date: 2024-03-01 DOI: 10.31138/mjr.171023.rof

Styliani Partalidou, Dimitrios Patoulias, Kleopatra Deuteraiou, Paraskevi Avgerou, George Kitas, Maria Tzitiridou-Chatzopoulou, Theodoros Dimitroulas

{"title":"Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism with JAK Inhibitors versus TNF Inhibitors in Rheumatoid Arthritis Patients: A Systematic Review and Meta-Analysis.","authors":"Styliani Partalidou, Dimitrios Patoulias, Kleopatra Deuteraiou, Paraskevi Avgerou, George Kitas, Maria Tzitiridou-Chatzopoulou, Theodoros Dimitroulas","doi":"10.31138/mjr.171023.rof","DOIUrl":"https://doi.org/10.31138/mjr.171023.rof","url":null,"abstract":"Objective: The aim of this study was to compare the risk of major cardiovascular events (MACE) and venous thromboembolic events (VTE) between tumour necrosis factor (TNF) and Janus kinase (JAK) inhibitors in patients with rheumatoid arthritis (RA).Methods: We researched PubMed, Scopus, Cochrane Library, and clinicaltrials.gov until December of 2023 for randomised controlled trials (RCTs) and observational studies. The outcomes studied were MACE (stroke, heart attack, myocardial infarction, sudden cardiac death) and VTE (deep vein thrombosis, pulmonary embolism). We pooled data using random effects model. Risk for the reported outcomes was expressed as odds ratio (OR) with a 95% confidential interval (CI). We performed a subgroup analysis based on study design.Results: We identified 23 studies, 20 of which compared the odds for MACE and 14 the odds for VTE between JAK and TNF inhibitors in RA patients. Ten studies were RCTs and the rest were observational. Regarding MACE risk we pooled data from a total of 215,278 patients (52,243 were treated with JAK inhibitors, while the rest 163,035 were under TNF inhibitors). Compared with TNF inhibitors, the OR for JAK inhibitors in regards with MACE risk was 0.87 (0.64-1.17, p<0.01). Regarding VTE, a total of 176,951 patients were analysed (41,375 JAK inhibitors users and 135,576 TNF inhibitors users). The OR for VTE for JAK inhibitors compared with TNF inhibitors was 1.28 (0.89-1.84, p<0.01).Conclusion: According to our results, there is no statistically significant difference for MACE or VTE in RA patients who receive either JAK or TNF inhibitors.","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"35 Suppl 1","pages":"10-19"},"PeriodicalIF":0.0,"publicationDate":"2024-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11094442/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140959244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

From Sand to Excellence: A Deep Dive into Abu Dhabi's Rheumatology Landscape. 从风沙到卓越：深入了解阿布扎比风湿病学现状。

Mediterranean Journal of Rheumatology Pub Date : 2024-02-12 eCollection Date: 2024-03-01 DOI: 10.31138/mjr.011123.fst

Khalid A Alnaqbi, Fahad Fazal, Rajaie Namas

引用次数: 0

Rheumatoid Arthritis Development following COVID-19 Infection: Eighth Case Described. 感染 COVID-19 后出现类风湿性关节炎：描述的第八个病例

Mediterranean Journal of Rheumatology Pub Date : 2024-02-12 eCollection Date: 2024-09-01 DOI: 10.31138/mjr.151122.rad

Jozélio Freire de Carvalho, Felipe Freire da Silva

引用次数: 0